Generic Name: margetuximab
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Margenza is a HER2 antibody approved for people with metastatic HER2-positive breast cancer who were previously treated with at least two other anti-HER2 inhibitors.
Maregnza is an engineered antibody that binds to HER2 receptors. About 20% of breast cancers have high expression of HER2, which plays a role in cell division and repair; blocking these receptors can slow cancer growth. Studies suggest Margenza also helps activate immune cells to fight cancer.
In the Phase III SOPHIA trial, people treated with Margenza plus chemotherapy had a 24% lower risk of disease progression or death than those who received Herceptin (trastuzumab) plus chemotherapy. Margenza was first approved in December 2020.
Margenza is administered as an intravenous infusion, usually every three weeks.
Common side effects of Margenza plus chemotherapy include fatigue, nausea, vomiting, diarrhea, constipation, decreased appetite, headache, fever, hair loss, muscle and joint pain, peripheral neuropathy, hand-foot syndrome (palmar-plantar erythrodysesthesia) and infusion reactions. Heart problems are a potential serious adverse event. Margenza can cause fetal harm if used during pregnancy.
For More Info: https://www.margenza.com/
Last Reviewed: December 20, 2020